Matthew Taylor
Stock Analyst at Jefferies
(3.34)
# 840
Out of 4,814 analysts
174
Total ratings
59.09%
Success rate
8.61%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $135 → $137 | $129.70 | +5.63% | 13 | Apr 17, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.92 | +0.54% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $62.37 | +65.14% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $71.56 | -2.17% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $246.95 | -9.70% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $82.70 | -8.10% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.35 | +5,219.15% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $152.40 | -20.60% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.83 | +394.70% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $16.86 | +166.98% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.61 | -17.87% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $15.80 | +235.44% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $7.32 | +227.87% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $346.60 | -0.46% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $97.88 | +32.82% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $277.77 | -17.20% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $13.92 | +43.73% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $48.54 | +75.11% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $72.35 | +3.66% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $211.49 | +15.84% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $28.89 | +114.61% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $129.55 | +62.10% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $10.54 | +13.91% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $68.61 | +82.19% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $95.25 | -47.51% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $482.40 | -56.47% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $35.52 | +170.27% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.34 | +199.79% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $200.40 | +32.73% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $9.53 | +67.89% | 2 | Jul 19, 2017 |
Abbott Laboratories
Apr 17, 2025
Maintains: Hold
Price Target: $135 → $137
Current: $129.70
Upside: +5.63%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.92
Upside: +0.54%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $62.37
Upside: +65.14%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $71.56
Upside: -2.17%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $246.95
Upside: -9.70%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $82.70
Upside: -8.10%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.35
Upside: +5,219.15%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $152.40
Upside: -20.60%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.83
Upside: +394.70%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $16.86
Upside: +166.98%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.61
Upside: -17.87%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $15.80
Upside: +235.44%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $7.32
Upside: +227.87%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $346.60
Upside: -0.46%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $97.88
Upside: +32.82%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $277.77
Upside: -17.20%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $13.92
Upside: +43.73%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $48.54
Upside: +75.11%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $72.35
Upside: +3.66%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $211.49
Upside: +15.84%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $28.89
Upside: +114.61%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $129.55
Upside: +62.10%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $10.54
Upside: +13.91%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $68.61
Upside: +82.19%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $95.25
Upside: -47.51%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $482.40
Upside: -56.47%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $35.52
Upside: +170.27%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.34
Upside: +199.79%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $200.40
Upside: +32.73%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.53
Upside: +67.89%